# BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Source: https://onco.cc/trials/nct07193511/  
OnCo record `nct07193511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AVZO-103 in bladder & urothelial cancer, run by Avenzo Therapeutics, Inc., now recruiting.

## Summary

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) is a phase 1/2 interventional study registered as NCT07193511 by Avenzo Therapeutics, Inc., with 355 participants planned, started 2025-10-02 and due to reach its primary completion in 2030-03. Interventions recorded: AVZO-103 and Combination Agent.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07193511
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sponsor: Avenzo Therapeutics, Inc.
- Enrolled: 355

## Sources

- ClinicalTrials.gov NCT07193511: https://clinicaltrials.gov/study/NCT07193511

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/)

---
JSON: https://onco.cc/api/v1/entities/nct07193511.json